Javascript must be enabled to use this form.

View Profile	Home Browse Faculty Facility Research Consortia Training Grants Courses Search Support About rSp Help and FAQ's Contact Us	GCC Home
Faculty Profile Last Modified Time: 10:26:33 AM Mon, 20 Apr 2020   Contact Information Laura Bover Associated Profiles  Professor, Director of Monoclonal Antibodies Core Facility, Genomic Medicine, Immunology, UT MD Anderson Cancer Center   MDA SCR4.3015 (Unit 902)    lbover@mdanderson.org     713-563-3301    Web Link    Lab Webpage    Dendritic Cells, Breast Neoplasms, Melanoma, Neoplasms, Tumors, Cell Line, Regulatory T-Lymphocytes, Cells    Associated Profiles Professional Preparation Research and Expertise Appointments  Professional Preparation  Degree Major Institution Year  PhD Biological Chemistry, Cell Biology, Oncology University Buenos Aires 1995  MSc Biological Chemistry University of Buenos Aires 1979  Research and Expertise Research Interests   During the last thirty years I have been working in cancer research, focused on the development of immunotherapeutic agents, such as MAbs and vaccines for the treatment of different types of cancer. I believe that tumor immunotherapy could only be successful if we trigger multiple checkpoints in the immune system, instructing it to see "cancer cells" as "viral-infected-cells", therefore leading to more effective antitumor immune responses. Specifically, my goals include the development and characterization of new MAbs raised against key molecules of the immune system, such as co-stimulatory and co-inhibitory molecules, thus activating or blocking their function when affects the anti-tumor response we desire to obtain. Another goal of my career is to assist other investigators, users of the MAF, with their own research projects, providing them my expertise and advise and developing the MAbs they need for their basic, translational and clinical research. Examples of successful antibodies developed at the Core are the anti-human OX40 antibody that blocks the function of inducible and natural Tregs (I am patent co-author) and the anti - PR1/ HLA-A2, a T cell receptor-like antibody that mediates complement dependent cytotoxicity against acute myeloid leukemia progenitor cells. Both of them are under clinical development.  Publications/Creative Works Click here to search for this faculty member's publications on PubMed.  Appointments Title Department / School Institution Professor, Director of Monoclonal Antibodies Core Facility Genomic Medicine, Immunology UT MD Anderson Cancer Center

powering - The Partnership
Important Disclaimer: The responsibility for the accuracy of the information contained on these pages lies with the authors and user providing such information.